Evidence map›Paper›PMID 12634965›Full record

Trial reportEuropean journal of nuclear medicine and molecular imaging2003

99mTc-interleukin-2 and (99m)Tc-HMPAO granulocyte scintigraphy in patients with inactive Crohn's disease.

Alessio Annovazzi, Livia Biancone, Renato Caviglia, Marco Chianelli, Gabriela Capriotti, Stephen J Mather, Renzo Caprilli, Francesco Pallone, Francesco Scopinaro, Alberto Signore

Abstract readClinical TrialComparative StudyControlled Clinical Trial
PubMed Publisher
In one paragraph

Trial report in European journal of nuclear medicine and molecular imaging, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 47 citations in OpenAlex.

  1. [European journal of nuclear medicine and molecular imaging · 2025
    Article
  2. Review
  3. Article
  4. Radiolabelling anReaction chemistry & engineering · 2021
    Article
  5. Toward Molecular Imaging of Intestinal Pathology.Inflammatory bowel diseases · 2020
    Review
  6. Frontiers in immunology · 2020
    Review
  7. Review
  8. EJNMMI research · 2019
    Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Identification of interleukin-2 for imaging atherosclerotic inflammation.European journal of nuclear medicine and molecular imaging · 2006
    Article
  17. 99mTc-interleukin-2 scintigraphy for the in vivo imaging of vulnerable atherosclerotic plaques.European journal of nuclear medicine and molecular imaging · 2006
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 2 countries.

Alessio AnnovazziNuclear Medicine Unit, Department of Clinical Sciences, Policlinico Umberto I, University La Sapienza, Rome, Italy.
Livia Biancone
Renato Caviglia
Marco Chianelli
Gabriela Capriotti
Stephen J Mather
Renzo Caprilli
Francesco Pallone
Francesco Scopinaro
Alberto Signore
Sapienza University of Rome · ITPoliclinico Umberto I · ITUniversity of Rome Tor Vergata · ITCampus Bio Medico University Hospital · ITCancer Research UK · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Crohn's disease (CD) is a chronic inflammatory bowel disease that may involve the whole gut. Marked intestinal T cell and macrophage activation is a key feature of the disease. Polymorphonuclear cell infiltration is also observed in the diseased gut, mainly during active inflammation. Scintigraphic detection of granulocytes and activated lymphocytes infiltrating the gut wall may be useful in identifying a subgroup of patients with clinically inactive CD who are undergoing early clinical relapse. The aims of the present study were (a) to compare the effectiveness of scintigraphy with (99m)Tc-labelled interleukin-2 ((99m)Tc-IL2) and with (99m)Tc-HMPAO labelled granulocytes ((99m)Tc-WBC) in detecting the presence and extent of bowel inflammation in patients with long-term inactive CD (>12 months) and (b) to assess the accuracy of these techniques in predicting future disease relapse. We studied 29 patients with ileal and/or colonic CD in stable clinical remission (Crohn's Disease Activity Index <150 for at least 12 months) using both (99m)Tc-IL2 and (99m)Tc-WBC scintigraphy in order to evaluate the extent of acute and chronic inflammation in the bowel. Planar and single-photon emission tomography images were acquired in each patient at 1 h p.i. For quantitative analysis of (99m)Tc-IL2 uptake, the abdomen was divided into 32 regions of interest. Despite the absence of symptoms, 18 patients (62%) showed a positive (99m)Tc-IL2 and 18 (62%) a positive (99m)Tc-WBC scan. Only 12 patients (41.4% of the total group) were positive on both scans, and the sites of IL2 and granulocyte bowel uptake were usually located in different segments, indicating that in CD, acute and chronic inflammation can be present in different sites. As far as the prognostic role of the two scans in predicting future disease relapse is concerned, both (99m)Tc-IL2 and (99m)Tc-WBC scintigraphy showed a high negative predictive value (1.00 and 0.91, respectively) but a weak positive predictive value (0.44 and 0.39, respectively). Nevertheless, Kaplan-Meier curves generated between scintigraphic findings and time free from disease relapse were statistically different only for (99m)Tc-IL2 scintigraphy (log-rank test, P=0.013). These results indicate that (99m)Tc-IL2 scintigraphy can be useful in selecting CD patients in clinical remission who could benefit from preventive therapy to avoid disease relapse.

Indexed as

Interleukin-2Organotechnetium CompoundsTechnetium Tc 99m ExametazimeCrohn DiseaseDisease-Free SurvivalFemaleGranulocytesHumansIntestinesMaleMesalamineMiddle AgedPredictive Value of TestsRadionuclide ImagingRadiopharmaceuticalsReproducibility of ResultsInterleukin-2MesalamineOrganotechnetium CompoundsRadiopharmaceuticalsTechnetium Tc 99m Exametazimetechnetium Tc 99m interleukin 2

Identifiers

PMID12634965
OpenAlexW2066668619

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.